Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

The headline reports late-breaking Phase 3 C-POST data on longer-term survival outcomes for adjuvant Libtayo (cemiplimab) in high-risk cutaneous squamous cell carcinoma after surgery and radiation. It provides no survival figures or direction of results, so the clinical and market impact cannot be determined from the text.